CimaVax is a cutting-edge therapeutic vaccine developed in Cuba, designed to treat non-small cell lung cancer (NSCLC). This vaccine targets the epidermal growth factor (EGF), a critical protein involved in cancer cell proliferation. CimaVax has garnered international recognition due to its unique mechanism of action, cost-efficiency, and promising clinical results. This document provides an in-depth...
AllCardiovascularChild DevelopmentCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized
Cimavax-EGF for Non-small Cell Lung Cancer Vaccine Cimavax-EGF is the first worldwide registered therapeutic vaccine for non-small lung cancer developed in Cuba by the Center for Molecular Immunology in conjunction with the Center for Genetic Engineering and Biotechnology. In 2008 it was approved by the Cuban regulatory authority for the use in adults with advanced...